as 11-15-2024 2:36pm EST
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Founded: | 2017 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 7.6M | IPO Year: | 2019 |
Target Price: | $4.75 | AVG Volume (30 days): | 1.0M |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.33 | EPS Growth: | N/A |
52 Week Low/High: | $0.58 - $1.73 | Next Earning Date: | 11-12-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
HOTH Breaking Stock News: Dive into HOTH Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
MT Newswires
17 days ago
MT Newswires
17 days ago
MT Newswires
17 days ago
PR Newswire
17 days ago
PR Newswire
a month ago
MT Newswires
2 months ago
PR Newswire
2 months ago
The information presented on this page, "HOTH Hoth Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.